Back to top
more

SPDR S&P Pharmaceuticals ETF: (XPH)

(Delayed Data from NYSE) As of Apr 15, 2024 04:00 PM ET

$39.63 USD

39.625
19,128

-0.53 (-1.31%)

Volume: 19,128

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

2 - Buy of 5   2      

After-Market: $39.73 +0.11 (0.26 %) 7:58 PM ET

Zacks News

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

Sweta Killa headshot

A Look at Pharma ETFs After Q4 Earnings

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. However, many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

Sweta Killa headshot

Pharma ETFs in Focus Post Q3 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Sweta Killa headshot

Pharma ETFs in Focus Post Q2 Earnings

Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.

Sanghamitra Saha headshot

Cautious on Big Tech & AI? Try These Value-Focused Sector ETFs

Value-focused investing comes to rescue if high-growth sectors fail for some reasons.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Sweta Killa headshot

Pharma ETFs Gain Post Q1 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Sweta Killa headshot

A Look at Pharma ETFs Post Q4 Earnings

Combining the actual results with the estimates for the still-to-report companies, total earnings for the healthcare sector are expected to decline 9% on revenue growth of 4.3%.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH

Sweta Killa headshot

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Sweta Killa headshot

Pharma ETFs in Focus Post Q3 Earnings

The Q3 earnings picture for the healthcare sector seems solid, with results from companies that have reported so far up 2.1% on 5.8% revenue growth.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

Sector ETF report for XPH